中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《2024年REDISCOVER国际指南: 交界可切除及局部晚期胰腺癌患者围手术期管理》解读

曾家辉 魏孔源 钱伟琨 王铮 韩亮

引用本文:
Citation:

《2024年REDISCOVER国际指南: 交界可切除及局部晚期胰腺癌患者围手术期管理》解读

DOI: 10.12449/JCH241110
基金项目: 

国家自然科学基金 (82172853)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:曾家辉、魏孔源负责指南翻译,分析讨论以及撰写论文;钱伟琨、王铮负责拟定写作思路,指导撰写文章;韩亮负责修改文章并最终定稿。
详细信息
    通信作者:

    韩亮, hanliangxjtu@163.com (ORCID: 0000-0002-3268-5214)

Interpretation of REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer (2024)

Research funding: 

National Natural Science Foundation of China (82172853)

More Information
  • 摘要: 2024年7月REDISCOVER国际指南共识小组发布了《交界可切除及局部晚期胰腺癌手术患者围手术期管理》,该规范基于目前临床存在的问题,从循证医学的角度出发,在交界可切除及局部晚期胰腺癌的诊断、分期及外科治疗等方面提出的推荐性意见具有重要意义,本文对该指南进行解读,以期更好地指导临床。

     

  • 图  1  文献筛选流程

    Figure  1.  Flow chart of systematic literature review

    图  2  REDISCOVER国际指南共识会议工作流程

    Figure  2.  Flow chart of the guideline process

  • [1] SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71( 1): 7- 33. DOI: 10.3322/caac.21654.
    [2] SESHACHARYULU P, BAINE MJ, SOUCHEK JJ, et al. Biological determinants of radioresistance and their remediation in pancreatic cancer[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868( 1): 69- 92. DOI: 10.1016/j.bbcan.2017.02.003.
    [3] BEAR AS, VONDERHEIDE RH, O’HARA MH. Challenges and opportunities for pancreatic cancer immunotherapy[J]. Cancer Cell, 2020, 38( 6): 788- 802. DOI: 10.1016/j.ccell.2020.08.004.
    [4] KATHER JN, HEIJ LR, GRABSCH HI, et al. Pan-cancer image-based detection of clinically actionable genetic alterations[J]. Nat Cancer, 2020, 1( 8): 789- 799. DOI: 10.1038/s43018-020-0087-6.
    [5] National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma(Version 2. 2023)[EB/OL].( 2023-10-22). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [6] BOGGI U, DEL CHIARO M, CROCE C, et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer[J]. Surgery, 2009, 146( 5): 869- 881. DOI: 10.1016/j.surg.2009.04.029.
    [7] ISAJI S, MIZUNO S, WINDSOR JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017[J]. Pancreatology, 2018, 18( 1): 2- 11. DOI: 10.1016/j.pan.2017.11.011.
    [8] OBA A, CROCE C, HOSOKAWA P, et al. Prognosis based definition of resectability in pancreatic cancer: A road map to new guidelines[J]. Ann Surg, 2022, 275( 1): 175- 181. DOI: 10.1097/SLA.0000000000003859.
    [9] MAGGINO L, MALLEO G, MARCHEGIANI G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma[J]. JAMA Surg, 2019, 154( 10): 932- 942. DOI: 10.1001/jamasurg.2019.2277.
    [10] CONROY T, PFEIFFER P, VILGRAIN V, et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34( 11): 987- 1002. DOI: 10.1016/j.annonc.2023.08.009.
    [11] LOOS M, MACK CE, XU ATL, et al. Distal pancreatectomy: Extent of resection determines surgical risk categories[J]. Ann Surg, 2024, 279( 3): 479- 485. DOI: 10.1097/SLA.0000000000005935.
    [12] LOOS M, AL-SAEEDI M, HINZ U, et al. Categorization of differing types of total pancreatectomy[J]. JAMA Surg, 2022, 157( 2): 120- 128. DOI: 10.1001/jamasurg.2021.5834.
    [13] BOGGI U, KAUFFMANN E, NAPOLI N, et al. REDISCOVER international guidelines on the perioperative care of surgical patients with borderline-resectable and locally advanced pancreatic cancer[J]. Ann Surg, 2024, 280( 1): 56- 65. DOI: 10.1097/SLA.0000000000006248.
    [14] BOCKHORN M, UZUNOGLU FG, ADHAM M, et al. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery(ISGPS)[J]. Surgery, 2014, 155( 6): 977- 988. DOI: 10.1016/j.surg.2014.02.001.
    [15] Scottish Intercollegiate Guidelines Network(SIGN). A guideline developer’s handbook[EB/OL].[ 2024-08-29]. https://www.sign.ac.uk/media/2038/sign50_2019.pdf. https://www.sign.ac.uk/media/2038/sign50_2019.pdf
    [16] Grading Tutorial[EB/OL].[ 2024-08-29]. https://www.uptodate.com/home/gradingtutorial. https://www.uptodate.com/home/gradingtutorial
    [17] BROUWERS MC, KHO ME, BROWMAN GP, et al. AGREE II: Advancing guideline development, reporting and evaluation in health care[J]. J Clin Epidemiol, 2010, 63( 12): 1308- 1311. DOI: 10.1016/j.jclinepi.2010.07.001.
    [18] J EJ, LINSTONE HA, TUROFF M. The Delphi method: Techniques and applications[J]. Technometrics, 1976, 18( 3): 363. DOI: 10.2307/1268751.
    [19] AJINA R, WEINER LM. T-cell immunity in pancreatic cancer[J]. Pancreas, 2020, 49( 8): 1014- 1023. DOI: 10.1097/MPA.0000000000001621.
    [20] NAPOLI N, KAUFFMANN EF, LOMBARDO C, et al. Postoperative results, learning curve, and outcomes of pancreatectomy with arterial resection: A single-center retrospective cohort study on 236 procedures[J]. Int J Surg, 2023, 110( 10): 6111- 6125. DOI: 10.1097/JS9.0000000000000971.
    [21] HE JX, LV N, YANG ZY, et al. Comparing upfront surgery with neoadjuvant treatments in patients with resectable, borderline resectable or locally advanced pancreatic cancer: A systematic review and network meta-analysis of randomized clinical trials[J]. Int J Surg, 2024, 110( 6): 3900- 3909. DOI: 10.1097/JS9.0000000000001313.
    [22] BOGGI U. Resection for pancreatic cancer with arterial involvement: A paradigm shift away from unresectable to“how to do it”[J]. Surgery, 2021, 169( 5): 1036. DOI: 10.1016/j.surg.2020.10.047.
    [23] REAMES BN, BLAIR AB, KRELL RW, et al. Management of locally advanced pancreatic cancer: Results of an international survey of current practice[J]. Ann Surg, 2021, 273( 6): 1173- 1181. DOI: 10.1097/SLA.0000000000003568.
    [24] National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma. Version 1.2024[EB/OL].( 2024-02-10). https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
    [25] SEELEN LWF, DOPPENBERG D, STOOP TF, et al. Minimum and optimal CA19-9 response after two months induction chemotherapy in patients with locally advanced pancreatic cancer: A nationwide multicenter study[J]. Ann Surg, 2024, 279( 5): 832- 841. DOI: 10.1097/SLA.0000000000006021.
    [26] REN L, JÄGER C, SCHORN S, et al. Arterial resection for pancreatic cancer: Feasibility and current standing in a high-volume center[J]. Ann Surg Open, 2023, 4( 3): e302. DOI: 10.1097/AS9.0000000000000302.
    [27] STOOP TF, MACKAY TM, BRADA LJH, et al. Pancreatectomy with arterial resection for periampullary cancer: Outcomes after planned or unplanned events in a nationwide, multicentre cohort[J]. Br J Surg, 2023, 110( 6): 638- 642. DOI: 10.1093/bjs/znac353.
    [28] FROMER MW, HAWTHORNE J, PHILIPS P, et al. An improved staging system for locally advanced pancreatic cancer: A critical need in the multidisciplinary era[J]. Ann Surg Oncol, 2021, 28( 11): 6201- 6210. DOI: 10.1245/s10434-021-10174-z.
    [29] BACHELLIER P, ROSSO E, FUCHSHUBER P, et al. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension[J]. Surgery, 2014, 155( 3): 449- 456. DOI: 10.1016/j.surg.2013.09.003.
    [30] BOGGI U, NAPOLI N, KAUFFMANN EF, et al. Pancreatectomy with resection and reconstruction of the superior mesenteric artery[J]. Br J Surg, 2023, 110( 8): 901- 904. DOI: 10.1093/bjs/znac363.
    [31] RATNAYAKE B, PENDHARKAR SA, CONNOR S, et al. Patient volume and clinical outcome after pancreatic cancer resection: A contemporary systematic review and meta-analysis[J]. Surgery, 2022, 172( 1): 273- 283. DOI: 10.1016/j.surg.2021.11.029.
    [32] KRAUTZ C, NIMPTSCH U, WEBER GF, et al. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany[J]. Ann Surg, 2018, 267( 3): 411- 417. DOI: 10.1097/SLA.0000000000002248.
    [33] VIVIAN E, BROOKS MR, LONGORIA R, et al. Improving the standard of care for all-a practical guide to developing a center of excellence[J]. Healthcare(Basel), 2021, 9( 6): 777. DOI: 10.3390/healthcare9060777.
    [34] GERO D, MULLER X, STAIGER RD, et al. How to establish benchmarks for surgical outcomes? A checklist based on an international expert Delphi consensus[J]. Ann Surg, 2022, 275( 1): 115- 120. DOI: 10.1097/SLA.0000000000003931.
    [35] FARGES O, BENDERSKY N, TRUANT S, et al. The theory and practice of pancreatic surgery in France[J]. Ann Surg, 2017, 266( 5): 797- 804. DOI: 10.1097/SLA.0000000000002399.
    [36] FARNES I, KLEIVE D, VERBEKE CS, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: Real-world data from a population-based, prospective cohort study(NORPACT-2)[J]. BJS Open, 2023, 7( 6): zrad137. DOI: 10.1093/bjsopen/zrad137.
    [37] VONLANTHEN R, LODGE P, BARKUN JS, et al. Toward a consensus on centralization in surgery[J]. Ann Surg, 2018, 268( 5): 712- 724. DOI: 10.1097/SLA.0000000000002965.
    [38] NAPOLI N, KAUFFMANN E, CACACE C, et al. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection[J]. Updates Surg, 2021, 73( 1): 233- 249. DOI: 10.1007/s13304-020-00883-7.
    [39] DIENER MK, MIHALJEVIC AL, STROBEL O, et al. Periarterial divestment in pancreatic cancer surgery[J]. Surgery, 2021, 169( 5): 1019- 1025. DOI: 10.1016/j.surg.2020.08.030.
    [40] NELSON DW, BLANCHARD TH, CAUSEY MW, et al. Examining the accuracy and clinical usefulness of intraoperative frozen section analysis in the management of pancreatic lesions[J]. Am J Surg, 2013, 205( 5): 613- 617. DOI: 10.1016/j.amjsurg.2013.01.015.
    [41] BOGGI U, KAUFFMANN EF, NAPOLI N, et al. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: Management algorithm, unanswered questions, and future perspectives[J]. Updates Surg, 2024, 76( 5): 1573- 1591. DOI: 10.1007/s13304-024-01860-0.
    [42] HEGER U, SUN HH, HINZ U, et al. Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival[J]. HPB(Oxford), 2020, 22( 2): 224- 232. DOI: 10.1016/j.hpb.2019.06.012.
    [43] NEWHOOK TE, VREELAND TJ, GRIFFIN JF, et al. Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma[J]. Ann Surg, 2023, 277( 3): 484- 490. DOI: 10.1097/SLA.0000000000005184.
    [44] TSAI S, GEORGE B, WITTMANN D, et al. Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer[J]. Ann Surg, 2020, 271( 4): 740- 747. DOI: 10.1097/SLA.0000000000003049.
    [45] van ROESSEL S, van VELDHUISEN E, KLOMPMAKER S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment[J]. JAMA Oncol, 2020, 6( 11): 1733- 1740. DOI: 10.1001/jamaoncol.2020.3537.
    [46] MA M, NIU TT, HAO Q, et al. Clinical effect analysis of stereotactic radiotherapy combined with concurrent chemoradiotherapy in the treatment of pancreatic cancer[J]. Trauma Crit Care Med, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.

    马明, 牛婷婷, 郝倩, 等. 立体定向放射治疗联合同步放化疗治疗胰腺癌临床效果分析[J]. 创伤与急危重病医学, 2022, 10( 5): 380- 381. DOI: 10.16048/j.issn.2095-5561.2022.05.18.
    [47] WANG CY, LIU XH, WANG XH, et al. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2018, 97( 36): e12260. DOI: 10.1097/MD.0000000000012260.
    [48] HOMMA Y, ENDO I, MATSUYAMA R, et al. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis[J]. J Hepatobiliary Pancreat Sci, 2022, 29( 5): 552- 561. DOI: 10.1002/jhbp.1127.
    [49] HASHIMOTO D, SATOI S, FUJII T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology(IAP)& the Japan Pancreas Society(JPS) 2022 in Kyoto[J]. Pancreatology, 2023, 23( 6): 682- 688. DOI: 10.1016/j.pan.2023.07.005.
    [50] GIANNONE F, CAPRETTI G, HILAL M ABU, et al. Resectability of pancreatic cancer is in the eye of the observer: A multicenter, blinded, prospective assessment of interobserver agreement on NCCN resectability status criteria[J]. Ann Surg Open, 2021, 2( 3): e087. DOI: 10.1097/AS9.0000000000000087.
    [51] GODHI SA, PARASAR K, SALUJA S, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2017, 265( 6): E73. DOI: 10.1097/SLA.0000000000001322.
  • 加载中
图(2)
计量
  • 文章访问数:  43
  • HTML全文浏览量:  19
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2024-08-29
  • 录用日期:  2024-09-25
  • 出版日期:  2024-11-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回